Oncolytics Biotech Inc.
ONCY
$0.80
-$0.01-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 87.09% | 112.92% | 85.73% | 101.72% | 11.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.66% | 84.84% | 32.03% | 38.45% | -19.64% |
| Operating Income | -101.66% | -84.84% | -32.03% | -38.45% | 19.64% |
| Income Before Tax | -79.08% | -96.20% | -37.67% | -52.23% | 0.33% |
| Income Tax Expenses | 65.57% | -- | 874.76% | -2,179.55% | -12.10% |
| Earnings from Continuing Operations | -78.93% | -96.20% | -40.40% | -49.43% | 0.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.93% | -96.20% | -40.40% | -49.43% | 0.48% |
| EBIT | -101.66% | -84.84% | -32.03% | -38.45% | 19.64% |
| EBITDA | -102.12% | -85.23% | -32.24% | -38.71% | 19.67% |
| EPS Basic | -36.03% | -47.76% | -2.45% | -13.66% | 16.79% |
| Normalized Basic EPS | -36.31% | -47.70% | -0.39% | -15.70% | 16.74% |
| EPS Diluted | -36.03% | -47.76% | -2.45% | -13.66% | 16.79% |
| Normalized Diluted EPS | -36.31% | -47.70% | -0.39% | -15.70% | 16.74% |
| Average Basic Shares Outstanding | 31.58% | 32.68% | 37.04% | 31.55% | 19.59% |
| Average Diluted Shares Outstanding | 31.58% | 32.68% | 37.04% | 31.55% | 19.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |